- Education, Training & Outreach
- Patients & Caregivers
- For Investigators
- News on Dementia
- Media Room
- Donate & Contact
University of Cambridge (November 28, 2011); Cambridge-Elan Centre for Research Innovation and Drug Discovery Launched
The University of Cambridge and Elan Corporation today announced the launch of The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at the University. The Cambridge-Elan Centre will provide a highly interdisciplinary environment uniquely positioned for delivering world-leading translational research focused on innovative therapies for Alzheimer's and Parkinson's diseases. This ten-year agreement paves the way for a long-term collaboration between Elan and the University of Cambridge.
Cambridge scientists have spent more than ten years engaged in interdisciplinary research in order to understand the fundamental molecular orgins of neurodegenerative disorders such as Alzheimer's and Parkinson's diseases. The primary goal of the new Centre will be to extend these activities to discover novel compounds and to characterise the fundamental physico-chemical mechanisms by which they alter the behaviour of proteins associated with neurodegenerative disorders.
Based on this understanding, in conjunction with scientists in Elan who are world leaders in the development of therapies to combat neurodegenerative disorders, these compounds will be translated into new treatments to prevent these diseases. The process of bringing together researchers at the University of Cambridge and Elan has already created novel insights and opportunities in drug discovery.